IGM Biosciences IncNASDAQ:IGMS
- LAST PRICE10.0400
- TODAY'S CHANGE (%)-0.3900 (-3.7392%)
- Bid / Lots9.0300/ 10
- Ask / Lots11.2000/ 1
- Open / Previous Close10.4600 / 10.4300
- Day Range
- 52 Week Range
- Volume68,190
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IGMS |
|---|---|---|
| 09:32 ET | 2046 | 10.46 |
| 09:33 ET | 745 | 10.4 |
| 09:44 ET | 4301 | 10.06 |
| 09:48 ET | 300 | 10.04 |
| 09:50 ET | 220 | 10.0562 |
| 09:51 ET | 100 | 10.31 |
| 09:53 ET | 300 | 10.245 |
| 09:55 ET | 200 | 10.48 |
| 10:02 ET | 200 | 10.4 |
| 10:08 ET | 100 | 10.4 |
| 10:15 ET | 388 | 10.3 |
| 10:18 ET | 980 | 10.12 |
| 10:20 ET | 200 | 10.11 |
| 10:24 ET | 456 | 10.145 |
| 10:26 ET | 100 | 10.21 |
| 10:31 ET | 206 | 10.239 |
| 10:33 ET | 100 | 10.2038 |
| 10:44 ET | 110 | 10.2803 |
| 11:05 ET | 100 | 10.16 |
| 11:09 ET | 400 | 10.2759 |
| 11:14 ET | 1889 | 10.07 |
| 11:16 ET | 739 | 9.995 |
| 11:36 ET | 450 | 9.94 |
| 11:38 ET | 100 | 9.9823 |
| 11:39 ET | 600 | 10 |
| 11:50 ET | 469 | 10.01 |
| 11:54 ET | 200 | 9.95 |
| 11:59 ET | 1550 | 9.8423 |
| 12:06 ET | 1751 | 9.77 |
| 12:08 ET | 408 | 9.78 |
| 12:10 ET | 100 | 9.77 |
| 12:14 ET | 1471 | 9.77 |
| 12:24 ET | 2813 | 9.77 |
| 12:26 ET | 1857 | 9.775 |
| 12:30 ET | 100 | 9.805 |
| 12:33 ET | 100 | 9.87 |
| 12:35 ET | 100 | 9.81 |
| 12:37 ET | 2856 | 9.815 |
| 12:39 ET | 500 | 9.92 |
| 12:46 ET | 100 | 10.04 |
| 12:50 ET | 400 | 10.12 |
| 12:55 ET | 504 | 10.05 |
| 12:57 ET | 100 | 10.07 |
| 01:00 ET | 12216 | 10.04 |
Nov 11, 2024
DJ IGM Biosciences Is Maintained at Buy by Stifel, from 11:30AM ET on Monday Nov 11, 2024 by Dow Jones
11:30AM ET on Monday Nov 11, 2024 by Dow Jones
Nov 8, 2024
IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update, from 7:00AM ET on Friday Nov 08, 2024 by Dow Jones
7:00AM ET on Friday Nov 08, 2024 by Dow Jones*DJ IGM Biosciences 3Q Loss/Shr $1.01 >IGMS, from 7:00AM ET on Friday Nov 08, 2024 by Dow Jones
7:00AM ET on Friday Nov 08, 2024 by Dow Jones
Nov 4, 2024
IGM Biosciences to Present at Three Upcoming Investor Conferences, from 7:00AM ET on Monday Nov 04, 2024 by Dow Jones
7:00AM ET on Monday Nov 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
IGM Biosciences Inc | 562.5M | -2.8x | --- |
Annexon Inc | 563.9M | -5.2x | --- |
Olema Pharmaceuticals Inc | 556.9M | -4.6x | --- |
Sana Biotechnology Inc | 547.0M | -2.0x | --- |
Humacyte Inc | 543.3M | -3.4x | --- |
ProKidney Corp | 539.6M | -3.6x | --- |
Company Information
IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. It is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.
Contact Information
- Headquarters
- 325 E Middlefield RdMOUNTAIN VIEW, CA, United States 94043-4003
- Phone
- 650-965-7873
- Fax
- 302-655-5049
Executives
- Chief Executive Officer, Director
- Mary Harler
- Chief Financial Officer
- Misbah Tahir
- Chief Business Officer
- Lisa Decker
- Independent Director
- Felix Baker
- Independent Director
- M. Kathleen Behrens
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $562.5M |
|---|---|
Revenue (TTM) | $2.9M |
Shares Outstanding | 59.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.09 |
EPS | $-3.65 |
Book Value | $3.46 |
P/E Ratio | -2.8x |
Price/Sales (TTM) | 192.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -8,043.83% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
